Zapnometinib (ATR-002)
Influenza
Key Facts
About Atriva Therapeutics
Atriva Therapeutics is a clinical-stage biotech pioneering a host-targeting antiviral strategy against major respiratory viruses. Its lead candidate, zapnometinib (ATR-002), is a MEK inhibitor repurposed to block the host kinase crucial for viral replication, currently in Phase 2 development for influenza and having completed a Phase 2 study for hospitalized COVID-19 patients. The company's platform has the potential to address high unmet medical needs, including pandemic preparedness, by developing broad-spectrum antivirals that may be less susceptible to viral resistance. As a private entity, Atriva is positioned in a competitive antiviral market but offers a differentiated mechanism of action.
View full company profileAbout Atriva Therapeutics
Atriva Therapeutics is a clinical-stage biotech pioneering a host-targeting antiviral strategy against major respiratory viruses. Its lead candidate, zapnometinib (ATR-002), is a MEK inhibitor repurposed to block the host kinase crucial for viral replication, currently in Phase 2 development for influenza and having completed a Phase 2 study for hospitalized COVID-19 patients. The company's platform has the potential to address high unmet medical needs, including pandemic preparedness, by developing broad-spectrum antivirals that may be less susceptible to viral resistance. As a private entity, Atriva is positioned in a competitive antiviral market but offers a differentiated mechanism of action.
View full company profileTherapeutic Areas
Other Influenza Drugs
| Drug | Company | Phase |
|---|---|---|
| PanCytoVir™ (oral probenecid) | TrippBio | IND Submitted |
| Mimotopes-004 | Mimotopes | Preclinical |
| Next-Gen / Universal Flu Vaccines | CSL Seqirus | Research / Early Clinical |
| Oseltamivir 75 mg | MSN Laboratories | Commercial |
| AI Programme - Influenza | Poolbeg Pharma | Discovery |
| Influenza Antibodies | new/era/mabs | Research/Pre-clinical |
| Influenza Countermeasure Program | DynPort Vaccines | Not Specified |
| Influenza Vaccine | Medigen | Preclinical |
| Nasal Influenza Vaccine | Abera Bioscience | Pre-clinical |
| EV25 | Eradivir | Pre-clinical |
| Not Specified | New Amsterdam Sciences | Pre-clinical |
| Influenza Program | Arisan Therapeutics | Preclinical |